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RESULTS: At a threshold of $100,000/QALY, the CEAC for PSA1 showed a 97% prob-
ability that TxB is cost-effective versus TxA, corresponding results for PSA2, and
PSA3, were 54%, and 58%, respectively. CONCLUSIONS: Failure to consider uncer-
tainties owing to PFS/OS data in oncology models, and to the ensuing calibration
procedures, can lead to under-representation of uncertainty in cost-effectiveness
results.
PCN132
MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC
ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN
PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
Danese MD1, Bracco A2, Macarios D3, Chung K3, Barlev A3, Halperin M1, Lothgren M2
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland,
3Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: Because bone metastases can cause costly SREs, lifetime estimates of
SREs prevented can help payers compare the effectiveness of treatment options. De-
nosumab was recently approved in the US for SRE prevention in patients with bone
metastases from solid tumors. This study presents amodel for SRE predictions based
on phase III trials comparing denosumab and ZA in different tumors. METHODS: A
three-state Markov model (On Treatment, Off Treatment, and Dead) was developed
using constant SRE incidence rates for each tumor type and treatment. Results were
comparedbetween themodeland trial for the3-year trial durationandextrapolated to
the patient lifetime. Lifetime SREs were estimated for the US population based on the
estimated annual number of newpatientswith bonemetastases.Mortality rateswere
identical between treatments and estimated using trial-based generalized gamma
distributions. Lifetime treatment was assumed. RESULTS: The number of all SREs
observed (rateper patient-year) for denosumabandZAwere 660 (0.488) and853 (0.631)
for breast cancer, 780 (0.746) and943 (0.947) for prostate cancer, and469 (0.588) and535
(0.690) for other solid tumors. Comparisonbetween trial results andmodel projections
over the trial time horizon resulted in differences in SRE counts ranging from -1.5% to
2.0%.Over the expectedpatient lifetime, estimatedSREsperpatientwere 1.80 and2.32
(denosumab and ZA) for breast cancer, 1.65 and 2.08 for prostate cancer, and 1.36 and
1.60 for other solid tumors. In annual incident cohorts of patients with bonemetasta-
ses, themodel projects 43,765 and 56,408 (denosumab and ZA) lifetime SREs in breast
cancer and 30,429 and 38,359 lifetime SREs in prostate cancer. CONCLUSIONS: The
model output is consistentwith the clinical trial evidence, and canbeused to compare
estimates of the predicted lifetime SREs for denosumab and ZA.
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OBJECTIVES:Accurate estimates of cancer epidemiology are fundamental to quan-
tifying the economic burden of cancer as well as supporting a variety of researches
in public health and commercial activities. However, the complete prevalence and
incidence of late-stage cancers is difficult to obtain as most surveillance programs
report cases at initial diagnosis, so recurrent cases, by definition are not captured.
The objective of this study is to present a simple mathematical approach to esti-
mate the epidemiology of late-stage cancers. METHODS: We developed an Excel-
based tool to estimate the epidemiology of late-stage cancerswithminimal historic
information. Data needed include annual national or local cancer-relatedmortality
rates, late-stage cancer survival rates and population size. Our approach starts
with the patients who died from the specific cancer and tracks back to estimate the
incidence and prevalence. The approach assumes most deaths attributed to the
cancer are late-stage disease. We tested our approach by estimating the incidence
and prevalence ofmetastatic breast cancer andmetastaticmelanomawith historic
mortality and survival data from the National Cancer Institute Surveillance, Epi-
demiology and End Results (SEER) Program. RESULTS:We estimated that the 2007
US incidence of stage IV breast cancer andmelanomawere approximately 32.4 per
100,000 women and 2.7 per 100,000 persons, respectively. These results corre-
sponded to a total of 49,505 patients (10,426 newly diagnosed and 39,079 recurrent
cases) for stage IV breast cancer and total of 8,279 patients (3,690 newly diagnosed
and 4,589 recurrent cases) for late-stage melanoma. Results are also available by
age and gender groups. CONCLUSIONS: Comparison of results using this epidemi-
ology tool with estimates from databases and chart review studies demonstrated
that our approach is reasonably accurate in its estimation. This approach could be
adopted for uncommon cancers or regions with scarce data.
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OBJECTIVES: Bladder cancer is a commonmalignancy with70,500 incident cases
per year in the US; 70% present as non-muscle invasive bladder cancer (NMIBC).
Perioperative instillation of chemotherapy after transurethral resection of the
bladder (TURBT) can reduce the risk of recurrence. Our objective was to estimate
the loss of quality-adjusted life years (QALY) due to unnecessary recurrences for
patients not receiving perioperative chemotherapy (PC). METHODS: A decision-
treemodel estimated the loss of QALYs following recurrence inNMIBC patients not
receiving PC. Therapy utilization rates were obtained from a chart review study of
1010 NMIBC patients treated by 259 US urologists. In this sample, 17% of patients
received PC after the initial TURBTand 27% received perioperative therapy after the
first recurrence. In addition, 48.6% received induction therapy with BCG (85%) or
mitomycin-C (MMC, 15%) after the first recurrence. The estimated 2-year recur-
rence rates in NMIBC patients were 53% with TURBT alone and 36% with TURBT
and PC. QALY estimates were obtained from literature with disutilities of0.10 for
each resection, 0.026 for BCG therapy, and an assumed 0.01 for MMC therapy.
RESULTS: According to estimates, 49,350 new cases of NMIBC are expected in the
US in 2010; 100% utilization of PC would result in avoidance of 6,962 bladder tumor
recurrences. Themodel estimates that 911 QALYs are lost over a 2-year time period
from preventable recurrences. This equates to 0.02 QALYs for all patients under-
going TURBT. An estimate of disutility at the first recurrence indicates a gain of
nearly 47 quality-adjusted days per avoidable recurrence and 8 days per new
NMIBC case if intravesical PCwas utilized.CONCLUSIONS:A substantial number of
QALYs are lost each year due to underuse of intravesical PC. Increased use of PC
could reduce the humanistic burden of unnecessary recurrences in NMIBC.
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OBJECTIVES: In 2010, an estimated 70,500 new cases of bladder cancer will be
diagnosed in the US; 70% will present as non-muscle invasive bladder cancer
(NMIBC). The instillation of intravesical chemotherapy after transurethral resec-
tion of bladder tumor (TURBT) can reduce the risk of tumor recurrence. The objec-
tive of this study is to estimate the economic consequences associated with un-
necessary recurrences in patients deprived of perioperative chemotherapy (PC).
METHODS: A decision-tree model estimated the economic consequences of recur-
rence in patients not receiving PC. Two sources were used to estimate rates for the
model because neither data source had both of the rates required; 1010 NMIBC
patient charts (from 259 US urologists) estimated therapy utilization, and recur-
rence rates were obtained from 502 patients enrolled in a trial by Tolley, et al.
randomizing patients to mitomycin C (MMC) versus no PC. Costs were estimated
using prevailing Medicare reimbursement rates for TURBT ($1,982), BCG induction
therapy ($201/instillation), MMC induction therapy ($252/instillation) and periop-
erative MMC ($166/instillation). RESULTS: Within the cohort, 17% of patients re-
ceived PC after the initial TURBT. The overall recurrence rate was 39%. At first
recurrence, 27% received PC and 48.6% received induction therapy with BCG (85%)
or MMC (15%). Data from the randomized trial indicate that at 2 years, 36% of
patients receiving PC recur compared with 53% receiving TURBT alone. Population
estimates predict 49,350 new cases of NMIBC in the US in 2010. The model demon-
strated prevention of 6962 bladder recurrenceswith perioperativeMMCafter initial
TURBT, with an estimated savings of $2608 per patient. This translates into aggre-
gate savings of $18.1 million to the US health care system over two years.
CONCLUSIONS: Greater use of PC after TURBT can reduce economic loss related to
preventable bladder tumor recurrences with substantial savings to the health care
system.
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OBJECTIVES:Although utility-based algorithms have been developed for the Func-
tional Assessment of Cancer Therapy (FACT), their properties are not well-known
compared to more widely used utility measures like the EQ-5D. The objective of
this study was to compare the properties and relationships between EQ-5D and
FACT-based health utility scores in cancer patients. METHODS: A retrospective
analysis was conducted on cross-sectional data collected from 534 cancer patients
who completed both FACT-G and EQ-5D. Properties of scores from 3 FACT-based
and 2 EQ-5D based algorithms were examined. Known groups comparisons were
based on physician and patient-rated ECOGperformance status. Relative efficiency
(RE) of the utility algorithms was examined using ratios of F-statistics. RESULTS:
Mean scores for the overall cohort were lowest using Kind and Macran’s FACT UK
societal (0.55, SD 0.09), followed by Dolan’s EQ-5D UK societal (0.72, SD 0.23),
Cheung et al.’s FACT mapped to EQ-5D (0.74, SD 0.11), Shaw et al.’s EQ-5D US
societal (0.79, SD 0.15), and highest using Dobrez et al’s FACT US patient algorithm
(0.83, SD 0.08). When stratified by ECOG status, the largest differences in mean
scores were generally observed for EQ-5D UK societal scores and smallest for the
FACT-based US patient scores; however, FACT UK societal scores had twice the
statistical efficiency of the other algorithms. CONCLUSIONS:We found important
differences in utilities scores estimated by each algorithm. The FACT-based algo-
rithms tended to underestimate the QALY benefit compared to the EQ-5D, and
appeared to driven by a more limited range of scale.
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OBJECTIVES: Faced with decreasing reimbursement costs, greater patient vol-
umes, higher operating costs and pressure to adopt quality standards, community
oncology practices and infusion centers operate in an increasingly challenging
environment. This study sought to assess the practice efficiency techniques cur-
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